Summary of Key Points Core Viewpoint - Zhongsheng Pharmaceutical (002317.SZ) experienced a significant decline in stock price, closing at 18.52 yuan with a drop of 6.28% on September 22 [1]. Trading Activity - Among the top five buyers of Zhongsheng Pharmaceutical, three were institutional special seats, indicating strong institutional interest in purchasing the stock [1]. - Conversely, four of the top five sellers were also institutional special seats, suggesting a notable level of institutional selling activity [1]. - The net selling amount by institutional seats reached 225.02 million yuan, highlighting a substantial outflow from institutional investors [1][2]. Transaction Details - The largest buying transaction was executed by a deep stock connection special seat, amounting to 180.28 million yuan, which accounted for 9.78% of the total transaction volume [3]. - The second largest buying transaction was also from an institutional special seat, totaling 31.77 million yuan, representing 1.72% of the total transaction volume [3]. - The largest selling transaction was again from a deep stock connection special seat, with a selling amount of 127.79 million yuan, which made up 6.93% of the total transaction volume [3].

众生药业今日跌6.28%，成交额18.43亿元，换手率12.79%，盘后龙虎榜数据显示，深股通专用席位买入 1.80亿元并卖出1.28亿元，3家机构专用席位净买入3077.48万元，有4家机构专用席位净卖出2.56亿元。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002317 | 众生药业 | 18.52 | -6.28% | 97.40万 | 18.43 Z | | 300878 | 维康药业 | 23.03 | -3.24% | 5.13万 | 1.20亿 | | 300391 | *ST长药 | 3.84 | -3.03% | 6.57万 | 2537.31万 | | 000590 | 启迪药业 | 11.87 | -2.94% | 8.56万 | 1.03亿 | | 833266 | 生物谷 | 10.64 | -2.21% | 1.89万 | 2036.57万 | | 300147 | ST香雪 | 10.96 | -1.79% | 13.06万 | 1.44亿 | | 600129 | 太极集团 | 21.30 | -1.71% | 8.86万 | 2006T | | 603139 | 康惠制药 | 22.27 | -1.68% | 1.58万 | 3546.98万 | | 600594 | 益 ...

格隆汇9月22日｜A股市场减肥药概念股走弱，其中，博瑞医药跌近10%，众生药业跌超8%，普洛药 业、普蕊斯跌超3%。 ...

Group 1 - The core viewpoint of the news is that the weight loss drug sector experienced a significant decline in stock prices after an initial rise, indicating volatility in this market segment [1] - Specifically, Borui Pharmaceutical saw a drop of over 10% after previously rising more than 9% [1] - Other companies in the sector, such as Zhongsheng Pharmaceutical, fell over 7%, while Tianenkang, Kexing Pharmaceutical, Baihua Pharmaceutical, and Jinkaishengke also experienced declines [1]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 21, 2025 [1] Core Insights - The trend of Chinese innovative drugs going global is a significant industry trend, with a notable increase in License-out transactions in the first half of 2025, surpassing the total number for 2024 by over half and increasing transaction amounts by 16% [2] - The report highlights the importance of structural opportunities within the industry, emphasizing the need to select high-quality companies amidst the competitive landscape [2] - The report notes that while the trend of innovative drugs going abroad continues, concerns have arisen due to fewer major transactions and proposed U.S. regulations affecting Chinese drug licensing [2] - The report identifies significant breakthroughs in small nucleic acid drugs, particularly in chronic disease areas such as hypertension, with notable partnerships and potential milestone payments [3] - The report discusses promising clinical data from Chinese ADCs presented at the World Lung Cancer Conference, showcasing competitive advantages in efficacy and safety [4] - The report mentions the advancements in GLP-1 analogs for weight loss, with ongoing developments from both multinational corporations and domestic companies [5] - The CXO sector is expected to gradually recover, driven by an increase in orders and favorable policy changes [6] - The report outlines the completion of expert reviews for the 2025 medical insurance negotiation and commercial insurance innovative drug directories, indicating potential impacts on participating companies [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index has underperformed compared to the CSI 300 index, with a recent weekly decline of 2.07% [22] - Over the past month, the industry has lagged behind the CSI 300 index by 7.79 percentage points [23] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 39.77, above the five-year historical average of 31.50 [48] 3. Recent Research Achievements - The report includes various recent research outputs, highlighting the ongoing focus on innovative drug development and market opportunities [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Medical Insurance Administration regarding drug directory adjustments and the implications for the industry [52][54]

Group 1 - The company held an investor reception day and mid-year performance briefing on September 19, 2023, with key management present [1] - Investors raised questions regarding new drug development, market expansion, and production capacity, to which the management provided detailed responses [2] - The company has established a commercial partnership with Sinovac Biotech for the overseas expansion of its drug, Anglatavir, in Macau and is actively pursuing international clinical applications and registrations [2] Group 2 - The company is the only domestic entity with innovative drugs for both COVID-19 and influenza, focusing on the commercialization of its products, Le Ruiling® and An Ruivei® [2] - The company is enhancing its marketing strategies through academic ecosystem development, data service upgrades, and key project practices to increase market share [2] - Ongoing clinical trials include RAY1225 for obesity, ZSP1601 for metabolic dysfunction-related fatty liver disease, and the commercialization of cyclosporine eye drops [2][3] Group 3 - Investors inquired about the company's overseas market development plans, traditional Chinese medicine growth, innovative drug insurance negotiations, stock performance, share buybacks, and executive shareholding [3] - The management assured compliance with relevant laws and regulations and emphasized timely information disclosure [3]

Group 1: New Drug Development and Market Expansion - The company has established a commercial partnership with Sinovac Biotech for the marketing of Anglave tablets in Macau, aiming to enhance its international presence [2] - Anglave, as the world's first PB2 inhibitor, shows significant efficacy against resistant strains, supported by endorsements from prominent experts [4] - The company is actively seeking domestic partners to expand into Hong Kong and ASEAN markets [4] Group 2: Production Capacity and Market Demand - The company has sufficient tablet production capacity and can adjust production based on market demand [2] - The potential market for Anglave is substantial, with optimistic projections suggesting it could outperform Oseltamivir, which generated over $3 billion in sales last year [6] Group 3: Financial Performance and Stock Market - The company's stock price has increased by 65.36% year-to-date, reflecting investor confidence in its transition to innovative drug development [15] - The company aims to maintain a stable development trajectory and enhance its market value through continuous innovation and effective management [28] Group 4: Clinical Trials and Regulatory Approvals - The company is progressing with the clinical trials for ZSP1601, a new drug for treating metabolic dysfunction-related fatty liver disease, currently in Phase IIb trials [13] - The company is also advancing the clinical trials for Anglave granules, targeting a significant pediatric and elderly patient population [15] Group 5: Strategic Focus and Future Outlook - The company emphasizes the importance of traditional Chinese medicine as a revenue source while pursuing innovative drug development for sustainable growth [15] - The management is committed to enhancing the company's reputation and visibility in the capital market to support its innovative drug initiatives [28]

Group 1 - The company is actively advancing the Phase III clinical trial of its innovative drug RAY1225, which is aimed at treating obesity/overweight patients and those with type 2 diabetes [2] - The company aims to complete the relevant research and apply for drug approval as soon as possible to provide more treatment options for patients [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002317 公告编号：2025-095 广东众生药业股份有限公司 第八届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十七次会议的会议通知于2025年9月 12日以专人形式送达全体董事，会议于2025年9月18日在公司会议室以现场和通讯表决方式召开。本次 会议应出席董事9人，实际出席董事9人。会议由公司董事长陈永红先生主持，全体监事、董事会秘书列 席会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。经与会董事认真审议，以 记名投票方式表决，做出如下决议： 一、审议通过了《关于使用部分闲置募集资金进行现金管理的议案》。 为提高募集资金使用效率，增加资金收益，公司在确保不影响募集资金投资计划正常进行的情况下，拟 使用不超过人民币18,000.00万元的闲置募集资金进行现金管理，适时购买结构性存款、大额存单等安全 性高的保本型产品。 现金管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限 ...